Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
复制标题
MCC-465（标记有新开发的单克隆抗体 GAH 的聚乙二醇化脂质体阿霉素）在结直肠癌异种移植物中的抗肿瘤作用
DOI：
10.1111/j.1349-7006.2004.tb02495.x
复制
发表时间：
2004
期刊：
影响因子：
5.7
通讯作者：
T. Kakizoe
中科院分区：
文献类型：
--
作者：
T. Hamaguchi;Y. Matsumura;Y. Nakanishi;K. Muro;Y. Yamada;Y. Shimada;K. Shirao;H. Niki;Saiko Hosokawa;T. Tagawa;T. Kakizoe
MCC-465是一种免疫脂质体包封的阿霉素。脂质体用聚乙二醇和名为GAH的单克隆抗体的F（ab）2标记，GAH是通过杂交瘤技术获得的人抗体。GAH识别的表位尚未得到很好的表征，但人胃癌、结直肠癌和乳腺癌细胞为GAH阳性，而正常对应物为GAH阴性。聚乙二醇化脂质体多柔比星（PLD）和MCC-465对GAH阴性Caco-2异种移植物未显示出显著的抗肿瘤活性。另一方面，与PLD相比，MCC-465对GAH阳性WiDr-Tc和SW 837异种移植物表现出显著上级抗肿瘤作用。GAH免疫组化显示94%（100/106）的结直肠癌手术标本为GAH阳性。这些结果保证了MCC-465用于转移性结直肠癌患者的I期临床试验。
MCC‐465 is an immunoliposome‐encapsulated doxorubicin. The liposome is tagged with polyethylene glycol and the F(ab)2 of a monoclonal antibody named GAH, a human antibody obtained by the hybridoma technique. The epitope recognized by GAH is not well characterized, but human gastric, colorectal, and mammary cancer cells were GAH‐positive, while the normal counterparts were GAH‐negative. Pegylated liposome doxorubicin (PLD) and MCC‐465 did not show significant antitumor activity against GAH‐negative Caco‐2 xenografts. On the other hand, MCC‐465 exhibited significantly superior antitumor effects against GAH‐positive WiDr‐Tc and SW837 xenografts, compared with PLD. Immunohis‐tochemistry with GAH revealed that 94% (100 of 106) of surgical specimens of colorectal cancer were GAH‐positive. These results warrant a phase I clinical trial of MCC‐465 for patients with metastatic colorectal cancer.
影响因子：
11.2
作者：
Y. Matsumura;H. Maeda
通讯作者：
Y. Matsumura;H. Maeda
影响因子：
45.3
作者：
Baselga, J;Tripathy, D;Norton, L
通讯作者：
Norton, L